# iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

> **NCT02802943** · PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 56 (estimated)

## Conditions studied

- Leukemia, Chronic Lymphatic

## Interventions

- **BIOLOGICAL:** Peptide Vaccine
- **DRUG:** Imiquimod

## Key facts

- **NCT ID:** NCT02802943
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-05
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-11-18
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2022-11-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802943, "iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02802943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*